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Summary Two hundred and eleven patients with node-positive stage 11 and IlIl breast cancer were treated with eight cycles of adjuvant
chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone
radical surgery, and 148 patients were treated with post-operative radiotherapy in two randomized studies. The impact of haematological
toxicity of CAFt on distant disease-free (DDFS) and overall survival (OS) was recorded. Dose intensity of all given cycles (Dl), dose intensity
of the two initial cycles (Dl2) and total dose (TD) were calculated separately for all chemotherapy drugs and were correlated with DDFS and
OS. Patients with a lower leucocyte nadir during the chemotherapy had significantly better DDFS and OS (P = 0.01 and 0.04 respectively).
Dose intensity of the two first cycles also correlated significantly with DDFS (P=0.05) in univariate but not in multivariate analysis, while the
leucocyte nadir retained its prognostic value. These results indicate that the leucocyte nadir during the adjuvant chemotherapy is a biological
marker of chemotherapy efficacy; this presents the possibility of establishing an optimal dose intensity for each patient. The initial dose
intensity of adjuvant chemotherapy also seems to be important in assuring the optimal effect of adjuvant chemotherapy.
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Dose intensity in chemotherapy is defined as the amount of drug
delivered per unit time. In a retrospective study on patients
included in a randomized trial ofadjuvant chemotherapy on node-
positive breast cancer, Bonadonna and Valagussa (1981) demon-
strated a significant correlation between unscheduled dose
reduction and reduced survival. Similar results have been
published subsequently from many retrospective studies in early
and advanced breast cancer (Rodriguez-Kraul et al, 1981; Tormey
et al, 1983; Howell et al, 1984; Senn et al, 1984; Ang et al, 1989;
Pronzato et al, 1989), however some retrospective studies have
failed to demonstrate any significant correlation between dose and
therapy efficacy (Ahmann et al, 1982; Glucksberg et al, 1982;
Redmond et al, 1983; Mouridsen et al, 1984; Velez-Garcia et al,
1987). A series of analyses on published chemotherapy studies
demonstrated that a positive correlation existed between the
scheduled amount of drug per unit time and the efficacy of
chemotherapy treatment on both early and advanced breast cancer
(Hryniuk and Bush, 1984; Hryniuk and Levine, 1986). Only a few
controlled prospective studies ofthe dose-response relationship in
breast cancer have been published, and the results have not been
consistent. A few studies have demonstrated a survival benefit
from receiving a higher dose intensity (Carmo-Pereira et al, 1987;
Tannock et al, 1988; Wood et al, 1994), while many controlled
studies have failed to demonstrate any dose-response relationship
(Hortobagyi et al, 1987a, b; Ludwig Breast Cancer Study Group,
1985; Walters et al, 1992; Fumoleau et al, 1993).
The retrospective calculation of dose-intensity has been criti-
cized by Henderson et al (1988). In retrospective analyses, the
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correlation between higher dose and better therapy results could
result from selection of patients with better tolerance to higher
chemotherapy doses. Redmond et al (1983) have published an
extensive review on the sources of error in retrospective correla-
tions between dose intensity and outcome. As an illustration ofthe
multiple sources of biases inherent in this kind of analysis, they
demonstrated a significant correlation ofdose intensity ofplacebo
and outcome in two NSABP trials.
One way to circumvent these biases would be to correlate some
biological measurement ofdose intensity with treatment outcome.
If the positive correlation between dose intensity and outcome
were the result of selection bias, one would expect patients
experiencing more toxicity to have the worse outcome, while the
opposite should be true if the correlation results from a true
dose-response effect. Perhaps the most important biological
measure ofdrug effect is the haematological toxicity, which is the
dose-limiting toxicity with most chemotherapy schedules.
The purpose ofthis study was to establish, through retrospective
analyses, if a better prognosis was associated with patients having
a lower leucocyte nadir (higher biological dose intensity) or with a
higher leucocyte nadir (higher dose intensity because of better
tolerance of chemotherapy). We also attempted to determine
whether dose reductions of doxorubicin-containing adjuvant
chemotherapy influenced the DDFS and OS of stage II and III
breast cancer patients.
PATIENTS AND METHODS
Patients
The study population comprised 211 primary breast cancer patients
who were included in two trials conducted simultaneously between
1981 and 1986 in Helsinki University Hospital, Department of
Radiotherapy and Oncology. One hundred and forty-nine of the
patients had stage II breast cancer and 62 stage III. All patients
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Table 1 Multivariate analyses of correlation between leucocyte count, initial dose intensities of doxorubicin and cyclophosphamide and DDFS and OS
DDFS OS No. of patients
Variable Hazard ratio (95% Cl) P-value Hazard ratio (95% Cl) P-value
Leucocyte nadir
Continuous 1.42 (1.13-1.78) 0.006 1.32 (1.03-1.68) 0.04 193
Categorical (109 1-
.4.0 1 (reference) 1 (reference) 11
3.0-3.9 1.03 (0.45-2.50) 1.02 (0.40-2.64) 35
2.0-2.9 0.57 (0.25-1.34) 0.69 (0.28-1.72) 81
<2.0 0.37 (0.15-0.91) 0.52 (0.20-1.37) 66
Doxorubicin initial dose intensity
Continuous 0.94 (0.85-1.05) 0.77 0.95 (0.85-1.06) 0.59 182
Categorical (%)
>90 1 (reference) 1 (reference) 48
80-89 0.83 (0.45-1.52) 0.78 (0.42-1.46) 46
70-79 1.08 (0.56-2.07) 1.09 (0.56-2.13) 56
60-69 1.21 (0.51-2.85) 1.56 (0.65-3.74) 18
<60 0.79 (0.20-3.19) 0.78 (0.19-3.21) 14
Cyclophosphamide initial dose intensity
Continuous 0.94 (0.84-1.06) 0.99 0.96 (0.85-1.09) 0.77 182
Categorical (%)
.90 1 (reference) 1 (reference) 37
80-89 1.51 (0.80-2.84) 1.54 (0.81-2.94) 71
70-79 1.32 (0.60-2.93) 0.84 (0.35-2.00) 40
60-69 1.26 (0.51-3.07) 0.99 (0.39-2.53) 22
<60 3.03 (0.70-13.04) 2.42 (0.55-10.68) 12
Patients were stratified by stage (II vs ll). The following variables were included: age (0-49, 50-59, 60 + years), oestrogen receptor status (negative < 10 ftmol,
positive > 10 ftmol), progesterone receptor status (negative < 10 ftmol, positive > 10 ftmol), adjuvant treatment (chemotherapy only vschemotherapy +
radiotherapy vs chemotherapy + radiotherapy + tamoxifen). Age, ER, PgR, group, doxorubicin and cyclophosphamide dose intensity during the first two cycles
had no significant effect on DDFS or OS.
underwent radical surgery and were treated with adjuvant
chemotherapy. This consisted of eight 4-weekly cycles of cyclo-
phosphamide (500 mg m-2) and doxorubicin, (40 mg m-2) adminis-
tered intravenously on day 1, and ftorafur, an oral analogue of
fluorouracil, (20 mg kg-') taken orally on days 1-14 (CAFt). Post-
operative irradiation was given between the second and third adju-
vant chemotherapy cycles using a cobolt source (45 Gy in 15
fractions) to regional nodes and operative scar. Adjuvant tamoxifen
was given from the first day and continued for 2 years at 40 mg per
day. Fifty-two stage II breast cancer patients were treated solely
with chemotherapy (IIC), 47 with chemotherapy and radiotherapy
(IIRC) and 50 with chemotherapy, radiotherapy and tamoxifen
(IIRCT). Thirty-one stage III breast cancer patients were treated
with chemotherapy and radiotherapy (IIIRC) and 31 with
chemotherapy, radiotherapy and tamoxifen (IIIRCT). Details of
these trials were published previously (Blomqvist et al, 1992;
Saarto et al, 1995). No effect of tamoxifen or radiotherapy on
distant disease-free survival or overall survival was demonstrated
in either ofthese two trials. Routine blood counts were taken during
every chemotherapy cycle, one day before treatment and approxi-
mately on day 10, in all patients during all chemotherapy cycles.
The mean age ofthepatients was 50.6 years. Oestrogen receptor
values were available for 170 patients, 48% of whom were
receptor positive. Progesterone receptor values were available for
171 patients, 45% of whom were receptor positive. One hundred
and two (51%) patients were over 50 years old. Median follow-up
time was 7.6 years.
Definitions and calculation of dose intensity
Individual records were taken of the dosage of each chemotherapy
drug, the duration oftreatment and the body surface area. Absolute
dose intensity was defined as the amount ofdrug administered per
unit body surface area (mg m-2) delivered per unit time (mg m-2
week-'). Relative dose intensity was calculated as delivered dose
intensity divided by projected dose intensity, according to Longo et
al (1991). The projected dose intensity is the total amount ofdrugs
scheduled in the protocol, dividedby the projected time schedule of
the entire treatment. Delivered dose intensity represents the total
amount ofdrug actually received, divided by the time taken for the
therapy. Dose intensities for each drug were calculated for the total
number ofcycles (DI) and for the two initial cycles (D12). Duration
oftreatment was defined as the interval (in weeks) between day one
ofthe firstcycle ofchemotherapy andday 28 ofthe lastgiven cycle.
For example, for a patient who received 450 mg m-2 cyclophos-
phamide and 35 mg m-2 doxorubicin (five cycles during 22
weeks), dose intensity of cyclophosphamide is [(450mg m-2 x 5)
/22 weeks]/125 mg m-2 weeks = 0.818 = 81.8% and dose intensity
of doxorubicin is [(35 mg m-2 x 5)/22 weeks]/10 mg m-2 week =
0.795 = 79.5%.
Statistical methods
Five-year cumulative DDFS and OS rates were calculated using
the Kaplan-Meier method (Kaplan and Meier, 1958). Multivariate
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Figure 1 Proportion with distant disease-free survival according to haematological toxicity in stage 11 and III patients. The times of censoring are depicted with
vertical bars
analyses were performed using the Cox regression technique (Cox,
1972) in EGRET software (SERC, 1988). Adjusted estimates were
obtained from a model containing age at diagnosis (0-49, 50-59,
60-70 years), oestrogen receptors (positive, negative and missing),
progesterone receptors (positive, negative and missing) and addi-
tional adjuvant therapy (none, radiotherapy, tamoxifen). Data for
ftorafur were excluded from analyses because they had no statisti-
cally significant effect on therapy results in either preliminary
univariate or multivariate analyses, and, furthermore, the data for
ftorafur dose intensity were missing for 32 patients (data not
shown). In the multivariate analysis, statistical significance was
determined on the basis of likelihood ratio tests. All tests were
two-sided and P-values less than or equal to 0.05 were considered
statistically significant.
Of the 211 eligible patients, data from eleven patients were
excluded from the analyses because they had not received the
planned chemotherapy (five patients refused chemotherapy, four
patients were not eligible for doxorubicin based chemotherapy
because they were suffering from other severe diseases, one patient
was excluded because of a non-radical operation and another
because of haematogenous metastases), and a further six were
excluded because they received only one cycle of chemotherapy
(n=194). In the analyses of prognostic effect of leucocyte, there
was one missing value (n=193). In analyses ofdose intensity from
the two initial cycles of chemotherapy, five patients had missing
information on drug doses (n=189), and in analyses of total dose
and dose intensity for all cycles, information of cumulative dose
was missing in four patients (n=190). Overall dose intensity, total
dose and efficacy ofhaematological toxicity were also analysed by
excluding all patients who had received less than four cycles of
chemotherapy (n=14) or whose treatment was interrupted because
of progression during chemotherapy (n=8). No patients experi-
enced disease progression during the first two cycles oftherapy.
RESULTS
Forty-nine patients (26%) discontinued chemotherapy as a result of
side-effects, mostly nausea and vomiting. The median number of
chemotherapy cycles was seven. Mean total dose of doxorubicin
was 240.7 mg m-2 (range 24-400 mg m-2, 86% ofthe planned total
dose. Mean total dose of cyclophosphamide was 2983.5 mg m-2
(range 366-4114 mg m-2), 75% of the planned total dose. Mean
dose intensity ofdoxorubicin was 70% (range 21.6-109.9%) and of
cyclophosphamide 70% (range 21.1-100%). Mean dose intensity
of doxorubicin during the first two cycles was 82% (39.3-125%),
and for cyclophosphamide it was also 82% (42-102.9%). The low
level of dose intensity was partly as a result of unscheduled initial
dose reductions of approximately 10%, which was later corrected
by dose escalation at subsequent courses according to tolerance.
Later dose reductions were mostly owing to leucopenia but, in
some cases, also because ofgastrointestinal side-effects.
In univariate analyses ofDDFS and OS in the patients who have
received at least two cycles ofchemotherapy, a statistically signif-
icant correlation between DDFS or OS and the nadir values of
leucocytes were established (P = 0.01 and P = 0.04 respectively).
Patients with lower leucocyte nadirs had significantly better DDFS
and OS than those patients with higher leucocyte nadir.
Doxorubicin dose intensity during the first two cycles of
chemotherapy correlated significantly to DDFS when all patients
received at least two cycles of chemotherapy were included
(P=0.05). The total dose of doxorubicin and cyclophosphamide
also correlated significantly to DDFS (P = 0.01 and P = 0.01
respectively) and OS (P = 0.01 and P = 0.01 respectively). Dose
intensity of all cycles had no significant correlation to chemo-
therapy outcome.
After exclusion of patients who relapsed during the chemo-
therapy or discontinued chemotherapy because of toxicity before
having received at least four cycles, a statistically significant
correlation between DDFS and leucocyte nadir was still estab-
lished (P = 0.05). However, total dose of doxorubicin and cyclo-
phosphamide were no longer significantly correlated, and dose
intensity of all cycles, as before, had no significant effect on treat-
ment outcome.
For multivariate analyses, age, hormonal receptor status, tamox-
ifen and radiotherapy treatment, delay between surgery and start of
chemotherapy were included in the Cox model, although none of
these variables had a statistically significant effect on outcome in
univariate analyses. All patients who had received at least two
cycles of chemotherapy were included in the analyses. In the
multivariate analysis, leucocyte nadir still correlated significantly
with DDFS and OS (P = 0.006 and P = 0.04 respectively), while
doxorubicin and cyclophosphamide dose intensities ofthe first two
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cycles lost their significance (Table 1). Similar correlation of
leucocyte nadir with DDFS and OS was seen in multivariate
analyses of stage II patients only (P = 0.007 and P = 0.058 respec-
tively) (Figure 1).
Median DDFS and OS for leucocyte nadir .4.0, 3-3.9 and < 3.0
(l09 1-' were 80 and 116, 90 and 111, and 126 and 128 months
respectively.
DISCUSSION
The interpretation of the dose-effect relationship in retrospective
studies is problematic. Redmond et al (1983) was able to demon-
strate, in retrospective analyses of 2 years' adjuvant chemotherapy,
a significant dose-response effect even in the placebo group
because of patients who discontinued therapy as a result of early
recurrence or therapy toxicity. Geller et al (1990) also demonstrated
that differences in disease-free survival (DFS) among patients in
different chemotherapy dose regimens could be attributed to early
recurrence. Our own results support these findings. The significant
correlation between total dose and chemotherapy outcome was lost
after excluding early failures who received lower doses because of
treatment discontinuation.
One way of overcoming selection bias is to use only the initial
dose intensity, as this might be less influenced by patient tolerance
and is not affected by subsequent treatment discontinuation. In this
study, we established a positive correlation between doxorubicin
dose intensity during the first two cycles and distant disease-free
survival (DDFS) No statistically significant correlation was found
between dose intensity of all cycles and outcome. In contrast to
our finding in a previous study, Hryniuk and Levine (1986)
demonstrated significant correlation between dose intensity of all
cycles and adjuvant chemotherapy outcome. However, the dose
intensity was calculated with the minimal duration of therapy (at
least six cycles ofchemotherapy), and this automatically included
early failures in the low-dose intensity group.
An even better way of overcoming selection bias is to correlate
treatment outcome with some biological measurement of dose
intensity, such as haematological toxicity which is perhaps the
most straightforward. The correlation between lower leucocyte
nadir and better outcome in the present study support a true
dose-response relationship. In fact, a few previous studies ofearly
and advanced breast cancer have also demonstrated a relationship
between lower leucocyte nadirs and either a higher response rate
or better DFS or OS (Ahmann et al, 1982; Samonigg et al, 1991;
Yosefet al, 1993).
The results of the present study indicate that leucocyte nadir is
an easy and reliable biological marker of chemotherapy efficacy.
Breast cancer adjuvant chemotherapy with fixed protocol doses
seemed to leave a group ofpatients who had better haematological
tolerance with ineffective levels ofdose intensity. More individual
planning ofchemotherapy doses is required. Using leucocyte nadir
as a marker for therapy efficacy provides the possibility of estab-
lishing an optimal chemotherapy dose intensity for individual
patients. The dose intensity during the initial cycles of
chemotherapy, in particular, seems to be significant in the opti-
mization of adjuvant chemotherapy.
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